Valbiotis SA (ALVAL.PA)
EUR 1.36
(-1.59%)
EUR 1.36
(-1.59%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -18.13 Million EUR | -32.88% |
| 2022 | -13.65 Million EUR | 4.05% |
| 2021 | -14.22 Million EUR | -87.89% |
| 2020 | -7.57 Million EUR | -132.48% |
| 2019 | -3.25 Million EUR | 29.46% |
| 2018 | -4.61 Million EUR | 48.16% |
| 2017 | -8.9 Million EUR | -3315.16% |
| 2016 | 277 Thousand EUR | 63.91% |
| 2015 | 169 Thousand EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q2 | -7.01 Million EUR | 0.0% |
| 2023 Q4 | -18.13 Million EUR | 0.0% |
| 2023 FY | -18.13 Million EUR | -32.88% |
| 2022 FY | -13.65 Million EUR | 4.05% |
| 2022 Q2 | -8.26 Million EUR | 0.0% |
| 2022 Q4 | -13.65 Million EUR | 0.0% |
| 2021 FY | -14.22 Million EUR | -87.89% |
| 2021 Q4 | -14.22 Million EUR | 0.0% |
| 2021 Q2 | -17.91 Million EUR | 0.0% |
| 2020 Q4 | -7.57 Million EUR | 0.0% |
| 2020 Q2 | -6.41 Million EUR | 0.0% |
| 2020 FY | -7.57 Million EUR | -132.48% |
| 2019 Q2 | 2.14 Million EUR | 0.0% |
| 2019 Q4 | -3.25 Million EUR | 0.0% |
| 2019 FY | -3.25 Million EUR | 29.46% |
| 2018 FY | -4.61 Million EUR | 48.16% |
| 2018 Q4 | -4.61 Million EUR | 0.0% |
| 2018 Q2 | -6.24 Million EUR | 0.0% |
| 2017 Q2 | -11.35 Million EUR | 0.0% |
| 2017 Q4 | -8.9 Million EUR | 0.0% |
| 2017 FY | -8.9 Million EUR | -3315.16% |
| 2016 Q4 | 277 Thousand EUR | 0.0% |
| 2016 FY | 277 Thousand EUR | 63.91% |
| 2015 FY | 169 Thousand EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | -2440.476% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 90.768% |
| Adocia SA | 127 Thousand EUR | 14382.677% |
| Aelis Farma SA | -16.19 Million EUR | -12.024% |
| Biophytis S.A. | 2.7 Million EUR | 771.069% |
| Advicenne S.A. | 12.17 Million EUR | 248.986% |
| genOway Société anonyme | 2.97 Million EUR | 710.131% |
| IntegraGen SA | -709.74 Thousand EUR | -2455.692% |
| Medesis Pharma S.A. | 1.15 Million EUR | 1666.124% |
| Neovacs S.A. | -237.08 Thousand EUR | -7550.778% |
| NFL Biosciences SA | -2.27 Million EUR | -697.014% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 516.365% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | -2083.98% |
| Sensorion SA | 1.37 Million EUR | 1416.116% |
| Theranexus Société Anonyme | 2.44 Million EUR | 842.138% |
| TME Pharma N.V. | -1.07 Million EUR | -1581.094% |
| TheraVet SA | 12.78 Thousand EUR | 141977.2% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | 932.064% |
| argenx SE | -1.83 Billion EUR | 99.012% |
| BioSenic S.A. | 28.04 Million EUR | 164.681% |
| Celyad Oncology SA | -6.1 Million EUR | -197.263% |
| DBV Technologies S.A. | -114.95 Million USD | 84.221% |
| Galapagos NV | -157.2 Million EUR | 88.462% |
| Genfit S.A. | -7.61 Million EUR | -138.326% |
| GeNeuro SA | 5.91 Million EUR | 406.9% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 27.768% |
| Innate Pharma S.A. | -30.71 Million EUR | 40.938% |
| Inventiva S.A. | 10.48 Million EUR | 272.934% |
| MaaT Pharma SA | -10.2 Million EUR | -77.746% |
| MedinCell S.A. | 39.5 Million EUR | 145.92% |
| Nanobiotix S.A. | -24.71 Million EUR | 26.616% |
| Onward Medical N.V. | -12.89 Million EUR | -40.678% |
| Oryzon Genomics S.A. | 1.43 Million EUR | 1368.165% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 166.862% |
| Oxurion NV | 10.71 Million EUR | 269.365% |
| Pharming Group N.V. | 99.4 Million EUR | 118.248% |
| Poxel S.A. | 44.55 Million EUR | 140.708% |
| GenSight Biologics S.A. | 16.29 Million EUR | 211.323% |
| Transgene SA | -14.4 Million EUR | -25.887% |
| Financière de Tubize SA | 78.62 Million EUR | 123.07% |
| UCB SA | 2.17 Billion EUR | 100.833% |
| Valneva SE | 82.73 Million EUR | 121.924% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 2.078% |